Congo trial of Ebola treatments switches to focus on two drugs

By Reuters For Citizen Digital

Published on: August 13, 2019 07:30 (EAT)

Congo trial of Ebola treatments switches to focus on two drugs — FILE - Health workers are seen inside the "red zone" of an Ebola treatment center, which was attacked in the early hours of March 9, 2019 in Butembo.

A clinical trial of four potential Ebola treatments in Congo has been narrowed to focus on two of the experimental drugs – Regeneron’s REGN-EB3 and a monoclonal antibody called mAb114 – after they showed encouraging results, scientists leading the trial said on Monday.

Two other experimental treatments – ZMapp, an intravenous treatment made by Mapp Biopharmaceutical and Remdesivir, made by Gilead Sciences, will now be dropped from the trial, the researchers said.

For Citizen TV updates
Join @citizentvke Telegram channel

Video Of The Day: | BULLDOZERS FOR SANITIZERS | Families remain in the cold after evictions from Kariobangi sewage estate